CorMedix Inc.
General ticker "CRMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $704.7M (TTM average)
CorMedix Inc. does not follow the US Stock Market performance with the rate: -2.0%.
Estimated limits based on current volatility of 1.8%: low 7.33$, high 7.60$
Factors to consider:
- Total employees count: 191 (+198.4%) as of 2025
- Top business risk factors: Operating losses, Regulatory and compliance, Clinical trial failure, Reimbursement changes, Construction delays
- Current price 14.6% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.50$, 15.21$]
- 2026-12-31 to 2027-12-31 estimated range: [8.21$, 14.76$]
Financial Metrics affecting the CRMD estimates:
- Positive: with PPE of 9.2 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 48.17 > 33.79
- Positive: 15.29 < Operating cash flow per share per price, % of 19.80
- Positive: 42.26 < Shareholder equity ratio, % of 49.06 <= 49.86
- Positive: Return on assets ratio (scaled to [-100,100]) of 16.48 > 10.70
- Positive: Interest expense per share per price, % of 0.31 <= 0.33
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of -6.18 <= -3.92
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term CRMD quotes
Long-term CRMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $43.47MM | $311.71MM |
| Operating Expenses | $48.96MM | $65.83MM | $161.57MM |
| Operating Income | $-48.96MM | $-22.36MM | $150.14MM |
| Non-Operating Income | $2.62MM | $3.03MM | $-0.12MM |
| Interest Expense | $0.03MM | $0.04MM | $2.78MM |
| R&D Expense | $13.16MM | $3.94MM | $19.33MM |
| Income(Loss) | $-46.34MM | $-19.32MM | $150.02MM |
| Taxes | $0.00MM | $-1.40MM | $-13.04MM |
| Net Income(Loss)* | $-46.34MM | $-17.93MM | $163.06MM |
| Stockholders Equity | $70.14MM | $84.66MM | $405.31MM |
| Inventory | $2.11MM | $7.60MM | $29.72MM |
| Assets | $82.06MM | $118.85MM | $826.14MM |
| Operating Cash Flow | $-38.41MM | $-50.61MM | $175.05MM |
| Capital expenditure | $0.33MM | $0.12MM | $2.26MM |
| Investing Cash Flow | $-17.06MM | $21.23MM | $-308.43MM |
| Financing Cash Flow | $55.92MM | $26.32MM | $238.45MM |
| Earnings Per Share** | $-0.91 | $-0.30 | $2.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.